Mavixen 100 MG / 40 MG (Glecaprevir / Pibrentasvir )

Basic Product Information of Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)

How Mavixen 100 MG/40 MG Works Dual-Target Pan-Genotypic HCV Inhibition Mechanism

Glecaprevir, the NS3/4A protease inhibitor component of Mavixen 100 MG/40 MG, targets the HCV NS3/4A serine protease the bifunctional viral enzyme responsible for cleaving the HCV polyprotein precursor at four cis- and trans-cleavage sites (NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B junctions), generating the mature non-structural viral proteins NS4A, NS4B, NS5A, and NS5B required for assembly of the intracellular HCV replication complex.

By engaging the NS3/4A catalytic serine residue with high-affinity, selective binding, glecaprevir blocks HCV polyprotein processing and prevents the intracellular assembly of the viral replication apparatus. Glecaprevir achieves potent pan-genotypic NS3/4A inhibition through a macrocyclic P1–P3 chemical scaffold that engages conserved catalytic residues across all six HCV genotypes (GT1 through GT6), producing uniform NS3/4A protease inhibitory activity irrespective of viral genotype, subtype, or the single-position resistance-associated substitutions (RASs) that limit the efficacy of first-generation NS3/4A protease inhibitors such as simeprevir, paritaprevir, and grazoprevir.

Pibrentasvir, the NS5A inhibitor component of Mavixen 100 MG/40 MG, targets HCV NS5A the multifunctional zinc-binding phosphoprotein that functions as the essential structural scaffold of the HCV membranous web replication complex and simultaneously orchestrates intracellular HCV RNA replication and extracellular virion assembly. Pibrentasvir binds to Domain I of NS5A with picomolar affinity, disrupting NS5A dimerisation and membrane association and collapsing the replication complex architecture.

Unlike first-generation NS5A inhibitors (ledipasvir, daclatasvir, ombitasvir, and velpatasvir), pibrentasvir maintains potent pan-genotypic NS5A inhibitory activity against the clinically prevalent resistance-associated substitutions (RASs) at NS5A positions Y93H, L31M/V, Q30E/H/R, and A92K across GT1 through GT6 providing a significant pharmacological advantage in patients harbouring pre-existing NS5A RASs that diminish first-generation NS5A inhibitor efficacy.

The combination of glecaprevir and pibrentasvir in Mavixen creates a high genetic barrier to HCV resistance: simultaneous emergence of resistance-conferring mutations at both the independent NS3/4A and NS5A viral targets during the compressed 8-week treatment course is pharmacologically negligible, confirmed by the near-zero on-treatment breakthrough rates observed across the Mavixen pivotal trial programme. Clinicians managing patients with chronic HCV infection can access Mavixen 100 MG/40 MG alongside a comprehensive range of specialty hepatology and oncology agents through Mediaid Pharmacy’s oncology medicines catalogue.

In the landmark pivotal clinical trial programme for glecaprevir/pibrentasvir, Mavixen 100 MG/40 MG demonstrated SVR12 rates of 99.1% in GT1 treatment-naive patients without cirrhosis (ENDURANCE-1, 8 weeks), 99.7% in GT2 treatment-naive patients without cirrhosis (ENDURANCE-2, 8 weeks), 95.3% in GT3 treatment-naive patients without cirrhosis (ENDURANCE-3, 8 weeks), ≥99% in GT4/5/6 treatment-naive patients without cirrhosis (ENDURANCE-4, 8 weeks), and 99.0% in treatment-naive patients with compensated cirrhosis across all genotypes (EXPEDITION-1, 12 weeks).

The EXPEDITION-4 trial established an SVR12 rate of 98.1% in patients with severe chronic kidney disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²) or on haemodialysis, confirming that Mavixen requires no dose adjustment for any degree of renal impairment the only approved interferon-free pangenotypic DAA regimen validated at this level of SVR12 efficacy in a dedicated Phase III dialysis trial.

Approved Indications for Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)

Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) is indicated for chronic HCV infection across four principal patient population categories, spanning all six HCV genotypes and multiple prior treatment experience profiles:

Key Clinical Benefits of Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)

How to Take Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) Dosage Guidelines

Clinical Monitoring Requirements During Mavixen (Glecaprevir/Pibrentasvir) Treatment

Comprehensive baseline and on-treatment laboratory monitoring is mandatory before and throughout Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) therapy. Before initiating Mavixen, prescribing clinicians must complete the following assessments without exception: Hepatitis B virus (HBV) serology HBsAg, anti-HBc (total or IgG), and anti-HBs is mandatory for all patients (Boxed Warning). HBV treatment-induced immune reconstitution can trigger HBV reactivation in patients with active HBV infection (HBsAg-positive) or, less commonly, in patients with resolved infection (HBsAg-negative, anti-HBc-positive).

HBsAg-positive patients must receive appropriate HBV antiviral prophylaxis (typically entecavir or tenofovir-based) initiated before or concurrently with Mavixen and continued per hepatology specialist guidance throughout the Mavixen course and post-treatment surveillance period. Anti-HBc-positive (HBsAg-negative) patients require periodic HBV DNA monitoring throughout the Mavixen course and the 12-week post-treatment follow-up period.

HCV RNA quantitative PCR (viral load) at baseline is required to confirm active HCV viraemia and establish a reference for on-treatment and post-treatment virological assessment. HCV genotyping and subtyping should be performed at baseline to determine the genotype-specific treatment duration applicable to each patient; while Mavixen’s pangenotypic activity eliminates genotype-dependence in regimen selection, genotyping directly determines whether the 8-, 12-, or 16-week course applies. The definitive clinical endpoint is HCV RNA undetectable at post-treatment week 12 (SVR12), confirming virological cure.

Liver function tests (serum ALT, AST, alkaline phosphatase, and total bilirubin) must be obtained at baseline; mild transient unconjugated hyperbilirubinaemia may occur during Mavixen therapy due to glecaprevir-mediated inhibition of the hepatic transporter UGT1A1 and does not represent hepatotoxicity. Hepatic fibrosis staging by liver elastography (FibroScan/transient elastography), FIB-4 index, APRI, or liver biopsy is required to confirm cirrhosis status and assign the correct treatment duration.

Renal function assessment (eGFR or serum creatinine) is recommended at baseline to document renal impairment category; no dose adjustment is required for any renal impairment category. Complete review of all concomitant medications including prescription drugs, over-the-counter products, herbal supplements, and antiretrovirals (in HIV co-infected patients) must be performed before Mavixen initiation to identify and manage clinically significant drug-drug interactions, particularly statin contraindications, atazanavir co-administration, and CYP3A4/P-gp inducer exposure.

Drug Interactions and Important Safety Information for Mavixen (Glecaprevir/Pibrentasvir)

Atazanavir (Absolutely Contraindicated): Co-administration of Mavixen (Glecaprevir/Pibrentasvir) with atazanavir as standalone HIV therapy or as a component of a cobicistat- or ritonavir-boosted atazanavir antiretroviral regimen is absolutely contraindicated. Atazanavir substantially increases glecaprevir plasma concentrations through combined hepatic uptake transporter inhibition (OATP1B1/1B3) and efflux transporter inhibition (P-gp/BCRP), significantly elevating hepatotoxicity risk. HIV-positive/HCV co-infected patients who require Mavixen treatment must have atazanavir replaced with a pharmacokinetically compatible alternative antiretroviral agent such as dolutegravir-, bictegravir-, or raltegravir-based regimens before Mavixen initiation.

Strong CYP3A4 and P-gp Inducers (Rifampicin Contraindicated; Carbamazepine, Phenytoin, Phenobarbital, St. John’s Wort Not Recommended): Potent inducers of CYP3A4 and/or P-glycoprotein including rifampicin (rifampin), carbamazepine, phenytoin, oxcarbazepine, phenobarbital, and St. John’s Wort (Hypericum perforatum) significantly reduce glecaprevir and pibrentasvir plasma exposures by accelerating their elimination, potentially reducing virological efficacy and SVR12 probability below the therapeutic threshold. Co-administration with rifampicin is contraindicated; co-administration with carbamazepine, phenytoin, phenobarbital, oxcarbazepine, and St. John’s Wort is not recommended. Clinicians must substitute all CYP3A4/P-gp inducer-based therapies with alternatives of lower inducing potential before starting Mavixen.

Statins (Multiple Contraindications and Dose Restrictions Review Required for All Patients): Glecaprevir and pibrentasvir inhibit the hepatic uptake transporters OATP1B1 and OATP1B3, as well as the efflux transporters P-gp and BCRP. Co-administration with HMG-CoA reductase inhibitors (statins) that are OATP1B1/1B3 and/or BCRP substrates may significantly increase statin plasma concentrations, elevating myopathy and rhabdomyolysis risk. Atorvastatin, lovastatin, and simvastatin are contraindicated with Mavixen due to marked statin plasma concentration increases. Rosuvastatin co-administration results in a significant rosuvastatin AUC increase and is also contraindicated or must be used at the lowest dose with close monitoring per local label. Fluvastatin is not recommended. Pravastatin may be co-administered at the lowest effective dose with monitoring for myopathy symptoms. Clinicians must conduct a complete statin medication review and implement appropriate statin substitution or dose reduction before prescribing Mavixen to any statin-treated patient.

Cyclosporine, Digoxin, and Narrow Therapeutic Index P-gp/OATP Substrates: Cyclosporine used in post-transplant HCV patients is a potent OATP1B1 and P-gp inhibitor that significantly increases glecaprevir plasma exposure; co-administration with cyclosporine at doses above 100 mg/day is not recommended due to elevated hepatotoxicity risk; cyclosporine ≤100 mg/day may be used with close monitoring. Hepatologists managing post-transplant HCV patients on high-dose cyclosporine must consider alternative DAA regimens or nephrology consultation for cyclosporine dose modification before initiating Mavixen.

Digoxin (P-gp substrate) plasma concentrations may be elevated by glecaprevir/pibrentasvir-mediated P-gp inhibition; digoxin serum levels must be measured before and periodically during Mavixen treatment. Dabigatran etexilate (direct oral anticoagulant; P-gp substrate) exposure may be increased; the combination should be used with caution and clinical monitoring for bleeding risk. All patients must provide a complete and accurate medication history including prescription drugs, over-the-counter agents, herbal preparations, and nutritional supplements to their hepatologist before starting Mavixen therapy.

Side Effects and Precautions of Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)

Who Should Use Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)?

Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) is indicated for adults and adolescents aged 12 years and older (weighing ≥45 kg) with chronic hepatitis C virus (HCV) infection across a broad spectrum of clinical presentations: treatment-naive patients infected with any HCV genotype (GT1 through GT6) with or without compensated cirrhosis (Child-Pugh A); patients who previously received and did not achieve SVR12 with pegylated interferon (Peg-IFN) alone, ribavirin (RBV) alone, or the combination of Peg-IFN/RBV provided they have not previously been treated with an NS5A replication complex inhibitor or an NS3/4A protease inhibitor; patients who received sofosbuvir-based therapy without an NS5A inhibitor or NS3/4A protease inhibitor and did not achieve SVR12; and patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or those requiring haemodialysis, for whom renally-cleared DAA regimens require dose modification or are not recommended.

Mavixen 100 MG/40 MG is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with any documented history of hepatic decompensation (ascites, hepatic encephalopathy, or variceal haemorrhage), and in patients previously treated with both an NS5A replication complex inhibitor and an NS3/4A protease inhibitor who did not achieve SVR12. Prescribing must be performed by or under the direct supervision of a hepatologist, gastroenterologist, or infectious disease specialist experienced in the management of chronic HCV infection and direct-acting antiviral therapy. For institutions and distributors requiring a comprehensive range of specialty hepatology, antiviral, and oncology medicines, Mediaid Pharmacy’s oncology and specialty medicines portfolio provides a complete range of targeted treatments sourced from verified international manufacturers.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)

Mediaid Pharmacy is a trusted global supplier of specialty antiviral and hepatology medications, supplying Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) with reliable worldwide shipping to South Asia, the Middle East, Africa, Southeast Asia, Europe, and beyond. Mavixen 100 MG/40 MG is registered for export and supplied in a 30-tablet pot (30’s Pot); a standard 8-week treatment course (3 tablets/day × 56 days = 168 tablets) requires approximately 6 pots, a 12-week course (252 tablets) requires approximately 9 pots, and a 16-week course (336 tablets) requires approximately 12 pots of 30 tablets. Our specialist team provides complete order support including pricing quotations, stock availability confirmation, regulatory and import documentation, certificate of analysis, and end-to-end international delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for all enquiries regarding Mavixen 100 MG/40 MG availability, pricing, and international delivery arrangements for your country.

Why Choose Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) from Mediaid Pharmacy?

Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir) represents a clinically proven and globally accessible glecaprevir/pibrentasvir formulation for the complete spectrum of chronic HCV patients treatment-naive and treatment-experienced, cirrhotic and non-cirrhotic, renally impaired and dialysis-dependent delivering SVR12 rates exceeding 97% across all six HCV genotypes in the pivotal ENDURANCE, EXPEDITION, and SURVEYOR-2 clinical trial series. The pangenotypic activity of Mavixen, delivered through a single fixed daily dose of three tablets (Glecaprevir 300 mg / Pibrentasvir 120 mg total) once daily with food, eliminates the need for genotype-specific regimen selection and reduces pre-treatment diagnostic requirements in resource-limited healthcare settings where HCV genotyping infrastructure may be unavailable or cost-prohibitive.

The 8-week treatment duration for treatment-naive patients without cirrhosis across all genotypes the shortest approved full-course pangenotypic HCV cure reduces total tablets per 8-week course to approximately 168, minimising patient fatigue, treatment dropout risk, and total antiviral medication cost per complete course of therapy. The 30-tablet pot design accommodates the flexible dispensing requirements of treatment courses spanning 8, 12, or 16 weeks and supports both institutional supply to hepatology centres and gastroenterology clinics and individual patient dispensing in all international markets.

Distributed globally by Mediaid Pharmacy with worldwide shipping, Mavixen 100 MG/40 MG gives patients and hepatology teams in both established and emerging healthcare markets access to validated, third-generation glecaprevir/pibrentasvir direct-acting antiviral therapy. For clinicians requiring a comprehensive range of specialty hepatology, antiviral, and oncology medicines alongside Mavixen, Mediaid Pharmacy’s oncology medicines section provides a complete portfolio of specialty treatments sourced from verified international manufacturers. For any hepatologist, gastroenterologist, or infectious disease specialist seeking a proven, pan-genotypic, and globally accessible glecaprevir/pibrentasvir option, Mavixen 100 MG/40 MG from Mediaid Pharmacy is the trusted clinical choice.

Frequently Asked Questions About Mavixen 100 MG/40 MG (Glecaprevir/Pibrentasvir)